Secondary procedures after endovascular aortic aneurysm repair  by Conners, Michael S. et al.
Secondary procedures after endovascular aortic
aneurysm repair
Michael S. Conners III, MD,a W. Charles Sternbergh III, MD,a Glen Carter, RT(R)(CV),a
Britt H. Tonnessen, MD,a Moises Yoselevitz, MD,b and Samuel R. Money, MD, MBA,a New Orleans, La
Purpose: The purpose of this study was to evaluate the incidence, distribution, and indications of secondary procedures
after endovascular aortic aneurysm repair (EAR).
Methods: At a single institution, 179 patients underwent EAR with four different endografts (AneuRx, n  117; Zenith,
n 49; Ancure, n 12; and Talent, n 1). The vascular section database was queried for patients who needed secondary
procedures after the original EAR. The mean time from EAR to the termination of the study was 27.0  16.7 months.
Type I or III endoleaks were treated aggressively. Type II endoleaks were treated only in the presence of aneurysm
expansion.
Results: Thirty-five (35/179; 19.6%) secondary procedures were performed in 32 patients. Indications for secondary
procedures included 14 limb occlusions or stenoses (40.0%), 13 endoleaks (37.1%), six endograft migrations (17.1%), one
delayed aneurysm rupture (2.8%), and one device malfunction (2.8%). Seven of the 10 early (<90 days) limb failures
(70%) occurred within the first 60 patients. At that time, a protocol with aggressive external iliac artery evaluation was
adopted. In the next 125 patients, the rate of early limb occlusion or stenosis was 2.4% (P .025, with Fisher exact test).
Distribution of secondary procedures included 23 endoluminal interventions (65.7%; angioplasty  stent placement,
thrombolysis, endocuff placement, embolization), eight traditional peripheral procedures (22.9%; femoral-femoral
bypass, thrombectomy), two laparoscopic interventions (5.7%; inferior mesenteric artery ligation), and two laparotomies
(5.7%; delayed conversions). Interventions for limb occlusion or stenosis occurred earliest (3.5  5.4 months; P < .05,
with analysis of variance), followed by treatment of endoleaks (14.3  12.9 months) and migration (27.5  10.4
months). The one delayed rupture occurred at 15.3 months.
Conclusion: Secondary procedures after EAR are common. Reinterventions can be grouped temporally on the basis of
indication. Treatment for limb ischemia is predominately early (>3 months), whereas treatment for endoleaks occurs at
approximately 1 year and interventions for migration predominate after 2 years. (J Vasc Surg 2002;36:992-6.)
Endovascular aortic aneurysm repair (EAR) may revo-
lutionize the management of infrarenal abdominal aortic
aneurysms. Its relative ease of insertion and reduction in
patient morbidity make it an attractive option to the tradi-
tional open repair. However, as many of the initial patients
approach the long-term follow-up period, deficiencies in
this new technology are becoming apparent. Some prob-
lems have been labeled device specific (hook fractures,
modular component separation, migration), and others
appear to be device independent (endoleaks). Regardless of
the mechanism of failure, the timing of such events is
unpredictable; therefore, life-long surveillance is para-
mount.
When problems do occur, secondary procedures are
frequently necessary and can range from simple percutane-
ous interventions to complex ruptured aneurysm repairs.
As the number of EARs increases, the number of secondary
procedures can be expected to increase as well. Early studies
report an incidence rate of secondary procedures after EAR
of 10% to 26%.1-4 The purpose of our study is to evaluate a
single institutional experience with secondary procedures
and to identify the temporal distribution of indications and
the management strategies.
MATERIALS AND METHODS
From December 1995 to December 2001, 185 indi-
viduals were scheduled for an endovascular aneurysm repair
at the Ochsner Clinic Foundation. During this time period,
four different endovascular prosthetic devices (Ancure/
Guidant [Menlo Park, Calif], AneuRx [Santa Rosa, Calif],
Talent/Medtronic [Sunrise, Fla], and Zenith/Cook
[Bloomington, Ind]) were implanted. All individuals were
evaluated before surgery with contrast-enhanced com-
puted tomographic (CT) imaging and selective use of
angiography. Specifics regarding our operative team, pref-
erence for regional anesthesia, and use of intraoperative
imaging have been published previously.5 Most patients
(63.7%) were involved in phase II/III US Food and Drug
Administration trials. Postoperative surveillance imaging
generally consisted of CT scan and plain abdominal radio-
graph at predetermined time intervals (before hospital dis-
charge and at 1 month, 6 months, and 12 months after
surgery). Unless indications deemed otherwise, surveil-
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lance imaging continued on a yearly basis. Imaging of
patients who elected to follow-up elsewhere was requested
from the primary physician.
Patient demographics, baseline aneurysm characteris-
tics, and subsequent outcome data were collected and
recorded in the vascular section database. Query of this
database supplemented with a retrospective review of pa-
tient medical records produced all data used in this manu-
script.
Patients. Subgroups of the patient cohort used in this
study have been reported in previous publications from our
institution.5,6 In concordance with the consensus state-
ment on submission and publication of manuscripts,7 this
study is an analysis of our database focused on a separate
issue (indications for secondary procedures after a temporal
pattern of occurrence) not previously addressed.
Definitions. A secondary procedure was defined as any
intervention after the original procedure that was related to
either the aneurysm or a complication of the original pro-
cedure. Secondary procedures were categorized first into
groups on the basis of the indication for reintervention and
second into groups on the basis of method of management
(open versus minimally invasive). Indications for secondary
procedures consisted of: 1, limb occlusion or stenosis; 2,
endoleak; 3, endograft migration; 4, delayed aneurysm
rupture; and 5, device malfunction. Any patient with mul-
tiple indications that were related (ie, device migration
leading to a proximal endoleak) was counted only under
the primary indication, but if the indications were not
related, then the patient was counted under each specific
indication (ie, separate type I and II endoleaks necessitating
treatment). An open technique consisted of any traditional
open procedure (ie, laparotomy, femoral-femoral bypass),
with the exception of femoral artery exposure for an endo-
vascular intervention. Minimally invasive management
consisted of all intraluminal manipulations (ie, angio-
plasty  stent placement, endocuff placement, emboliza-
tion techniques, and thrombolysis) and laparoscopic pro-
cedures (inferior mesenteric artery [IMA] ligation).
Statistics. All patient demographics and aneurysm
characteristics are reported as the mean  the standard
deviation. A multivariate time-dependent Cox regression
analysis was used to test for differences in gender, patient
age, aneurysm size, and time from implantation. Analysis of
variance was used to identify significant differences in mean
time from implantation until the secondary procedure for
patients with limb occlusion or stenosis, endoleak, and
endograft migration. 2 analysis and Fisher exact test were
used to test for differences in the rate of early limb occlu-
sion.
RESULTS
During the 73-month period, 179 patients (96.8%)
were treated with an endovascular device. Six individuals
(3.2%) underwent either acute conversion to an open repair
(n 4) or an aborted failed endovascular attempt (n 2).
The 1-year mortality rate was 10.6%, and no death was
attributed to a secondary procedure (mortality rate includes
two patients in whom the length of survival was unknown
but assumed to be less than 1 year). The average age of the
patients was 72.9 7.2 years, with a male to female ratio of
8.7:1. The mean time from endograft implantation to the
study cutoff date (December 31, 2001) was 27.0  16.7
months. Mean aneurysm size was 56.1  11.2 mm.
The indications for secondary procedures are detailed
in Table I. Of those patients with successful endograft
placement, 7.3% were treated for limb occlusion or steno-
sis, 6.1% needed treatment for an endoleak, and 3.4%
underwent a secondary procedure for endograft migration.
One patient (0.6%) was treated for delayed aneurysm rup-
ture, and another needed (0.6%) an additional procedure
for device malfunction.
Thirty-five secondary procedures (19.6%) were per-
formed in 32 patients. Two patients underwent multiple
secondary procedures (one patient needed three secondary
procedures and the other needed two). These additional
procedures account for the discrepancy between the sec-
ondary procedure rate and the percentage of patients need-
ing a secondary procedure (19.6% versus 17.9%, respec-
tively; Table I). The average time until the secondary
procedure was 11.9  12.8 months after implantation.
Age, aneurysm size, gender, and time from implantation
did not significantly differ in patients with a secondary
procedure (Table II). The distribution of indications for a
secondary procedure (Fig) was limb occlusion or stenosis
(40.0%), endoleak (37.1%), endograft migration (17.1%),
delayed aneurysm rupture (2.8%), and device malfunction
(2.8%). The single device malfunction involved a situation
in which the contralateral limb failed to deploy and the
EAR was aborted with the patient missing the contralateral
limb (no appropriate graft was available in the hospital).
The patient was returned to the operating room for com-
pletion of the EAR 28 days later. Our only delayed rupture
Table I. Number and percentage of secondary
procedures by indication*
Reason No. Patients
Limb occlusion/stenosis 14 (7.8%) 13 (7.3%)
Endoleak 13 (7.3%) 11 (6.1%)
Migration 6 (3.4%) 6 (3.4%)
Rupture 1 (0.6%) 1 (0.6%)
Device malfunction 1 (0.6%) 1 (0.6%)
Total 35 (19.6%) 32 (17.9%)
*Two patients needed multiple procedures.
Table II. Patient characteristics
No
procedure
Secondary
procedure P value
Age (y) 73.1  7.1 72.2  7.9 .55
AAA size (mm) 55.9  11.3 56.8  10.5 .70
Time from implant (mo) 25.9  17.2 31.8  13.2 .07
Gender male:female 9.2:1 7:1 .79
AAA, Abdominal aortic aneurysm.
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occurred at 15.3 months after implantation. This patient
survived an emergent open aneurysm repair. The mean
time from endograft implantation until the secondary pro-
cedure for patients with limb occlusion or stenosis, en-
doleak, and endograft migration was 3.5  5.4 months,
14.3 12.9 months, and 27.5 10.4 months, respectively
(P  .05).
In the first 60 endovascular aneurysm repairs, eight
patients (13.3%) had a limb occlusion or stenosis after
surgery, and seven of these occurred within the first 90
days. At that time, a protocol was adopted with a more
aggressive external iliac evaluation after completion of the
EAR. This was performed via a retrograde angiogram dur-
ing surgery through the introducer sheath. In the next 125
procedures, only five patients (4.0%) had a problem with
limb occlusion or stenosis, and three of these occurred early
(90 days). This increased surveillance for occult iliac
disease resulted in a statistically significant reduction in
early limb occlusion or stenosis (11.7% versus 2.4%; P 
.025, with Fisher exact test).
Thirty-seven of our patients (20.7%) showed evidence
of an endoleak at some time during the follow-up period.
Only 11 of these patients (29.7%) with an endoleak needed
a secondary intervention directed at the endoleak. One of
these patients needed three secondary procedures: 1, an
initial attempt at laparoscopic IMA ligation; followed by 2,
a second successful attempt 2 days later; and 3, placement
of an endocuff 3.5 years after implantation for the develop-
ment of a proximal type I endoleak. In total, six type I, six
type II, and one type III endoleak needed secondary pro-
cedures.
The distribution of secondary procedures consisted of
23 endoluminal interventions (65.7%; angioplasty  stent
placement, thrombolysis, endocuff placement, emboliza-
tion), eight traditional peripheral procedures (22.9%; fem-
oral-femoral bypass, thrombectomy), two laparoscopies
(5.7%; IMA ligation), and two formal laparotomies (5.7%;
delayed conversions). Overall, 69.7% of the secondary pro-
cedures were accomplished with a minimally invasive tech-
nique. Two secondary procedures failed and needed addi-
tional interventions. One patient had failed thrombolysis
and subsequently needed a femoral-femoral bypass, and the
other patient needed a second laparoscopic IMA ligation
because of laparoscopic clipping of a branch of the IMA
initially.
Evaluating management strategies on the basis of the
indication for the secondary procedure revealed that only
35.7% (5/14) of limb occlusions or stenoses were managed
with a minimally invasive procedure. Of the five patients
with endoluminal management, four underwent thrombol-
ysis ( stenting) and the remaining one had angioplasty
and stenting. The other eight patients with limb occlusion
or stenosis received either a femoral-femoral bypass (n 6)
or a thrombectomy (n  2) procedure. As mentioned
previously, one of the eight patients had a failed attempt at
thrombolysis and needed open procedure. All patients with
endograft migration underwent management with an en-
docuff. Management of endoleaks was usually accom-
plished with a minimally invasive procedure (92.3% or
12/13) that consisted of angioplasty (n  1), laparoscopic
IMA ligation (n  2), intraluminal embolization (n  4),
or endocuff placement (n  5). One patient with an en-
doleak and expanding aneurysm underwent conversion to
an open aneurysm repair after unsuccessful attempts at
identifying the area responsible for the endoleak.
DISCUSSION
Since it was first introduced approximately a decade
ago, endovascular repair of abdominal aortic aneurysms has
replaced many of the open procedures. Despite some con-
troversy regarding equivalent perioperative mortality rates
when compared with conventional open repair, EAR has
been shown to be associated with reductions in blood loss,
perioperative major morbidity, and length of hospital stay.8
These advantages in conjunction with the high rate of
short-term success make this new technique ideal for pa-
tients with conditions deemed unfit for conventional open
aneurysm repair.
Disadvantages associated with EAR include anatomic
limitations and unknown long-term durability. Currently,
anatomic limitations center on proximal and distal neck
length, neck angulation,5 tortuosity, and vessel diameter.
Modifications in device designs will hopefully reduce cur-
rent anatomic restraints. As many of the initial patients
approach the long-term follow-up period, the number of
reported deficiencies associated with this new technology is
accumulating.6,9-12 In addition, that many patients will
need secondary procedures to maintain either patency of
the endograft or exclusion of the aneurysm is becoming
clear. Laheij and colleagues3 evaluated the EUROSTAR
data and found reintervention rates similar to our results. In
1023 patients, with at least 12 months of follow-up, 18%
needed a secondary procedure at a mean of 14 months after
the original procedure. Zarins et al2 found slightly lower
rates when evaluating the 4-year results and worldwide
Distribution of indications.
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experience with the AneuRx stent graft. In this report,
approximately 12% of patients needed a secondary proce-
dure by 3 years after implantation. Ho¨lzenbein and col-
leagues4 reported on a smaller series in which four different
endografts were used in 166 patients with a median fol-
low-up period of 18 months. In their experience, 26.6% of
patients needed a reintervention. The importance of these
studies is two-fold. First, they show that the rate of second-
ary procedures associated with EAR is not insignificant.
Second, they report results obtained with many different
endograft designs, all of which appear to necessitate main-
tenance procedures.
Overall, we found a 19.6% secondary procedure rate
after EAR. The indications for secondary interventions
were predominately limb occlusion or stenosis (40.0%),
endoleak (37.1%), and endograft migration (17.1%). Treat-
ment for these indications followed a temporal pattern of
occurrence. Secondary procedures for limb ischemia gen-
erally occurred early (at approximately 3 months), whereas
treatment for endoleaks occurred approximately 1 year
after implantation and interventions for endograft migra-
tion typically occurred after 2 years. The rather short time
from implantation to reintervention (3.5 5.4 months) for
limb ischemia suggest that problems with limb occlusion or
stenosis were generally the result of occult iliac artery or
endograft limb stenosis. Our learning curve with iliac artery
evaluation became evident after the first 60 implantations.
At that point, we had an early (90 days) limb occlusion or
stenosis rate of 11.7%. With this realization, we adopted a
more aggressive approach to evaluating the iliac arteries and
significantly reduced the early (90 days) limb occlusion or
stenosis rate to 2.4%. Zarins et al13 had similar early limb
occlusion rates (2%) when evaluating 398 patients with a
mean follow-up period of 10 4 months. Their time from
implantation to reintervention was not dissimilar to ours
and ranged from 1 week to 6 months after implantation. In
another study involving 239 patients, Ohki et al1 found a
2.9% reintervention rate for limb occlusion or stenosis with
a mean time from implant of 7.4 months.
In regard to endoleaks, our practice has been to aggres-
sively treat type I and III endoleaks and to only treat type II
endoleaks in the face of aneurysm expansion. With these
guidelines, 6.1% (11/179) of our patients were treated for
endoleaks. One patient needed multiple reinterventions,
yielding a 7.1% secondary procedure rate for the treatment
of endoleaks. Similarly, Zarins et al13 and Ohki et al1 found
secondary intervention rates for endoleaks to be between
4% and 5.9%. Time from implantation to reintervention for
the treatment of endoleaks is typically later than that seen
for limb ischemia (3.5  5.4 months versus 14.3  12.9
months). Reasons for this discrepancy may involve the
delayed appearance of secondary type I endoleaks associ-
ated with aneurysm remodeling. Of the six patients treated
for a type I endoleak, five were noticed at the 1-year CT
scan. Second, type II endoleaks were generally managed
with observation until aneurysm expansion was identified,
thus prolonging the time interval until reintervention.
Endograft migration is an increasingly common indica-
tion for secondary intervention. According to the Lifeline
Registry reporting standards, migration is considered to be
movement of the endograft 5 mm or more.14 In an earlier
report from our institution, we reported cumulative migra-
tion rates with the AneuRx endograft of 7.2%, 20.4%, and
42.1% for 1 year, 2 years, and 3 years after implantation,
respectively.6 Enlargement of proximal aneurysm neck di-
ameter was found to be significantly related to device
migration. Importantly, new migrations were found within
each subsequent year of follow-up. The timing of treatment
for this indication is a reflection of the increasing risk as the
patient progresses from the date of implantation.
Because these particular complications (limb occlusion
or stenosis, endoleak, and device migration) appear to
necessitate attention at different time intervals, it is impor-
tant to adhere to a structured follow-up program. We have
continued a similar follow-up regimen initiated and recom-
mended by the various US Food and Drug Administration
endograft trials. In general, this consists of a CT scan with
and without intravenous contrast and two views of a plain
abdominal radiograph at 1 month, 6 months, and 1 year
after implantation. After this surveillance, imaging is con-
tinued on a yearly basis unless indications demand other-
wise. Patients with any migration (treated or untreated) or
who are believed to have a higher risk of delayed complica-
tions are studied at a minimum of every 6 months.
From a management standpoint, most procedures after
EAR can be accomplished with minimally invasive tech-
niques. The exception to this in our series was the patient
with limb occlusion or stenosis. Of patients with limb
ischemia, 61.5% needed open procedures. Similarly, in
both studies by Zarins et al13 and Ohki et al,1 six of seven
patients with limb occlusion or stenosis needed traditional
open procedures. On the contrary, management of en-
doleaks and endograft migration can usually be accom-
plished with a minimally invasive technique.
We did not attempt to identify a difference in regard to
secondary procedures among the different endografts.
First, the number of patients with Ancure or Talent devices
was too small. Second, although the number of patients
with AneuRx or Zenith devices was larger, the follow-up
time period for these two endografts was significantly dif-
ferent (28.5 13.2 versus 13.1 5.5 months, respectively;
P .05). With many interventions for endoleaks occurring
near 1 year and most treatments for migration after 2 years,
fair comparisons were not possible.
CONCLUSION
Secondary procedures after EAR are common (19.6%)
and appear to be temporally spaced on the basis of the
indication for the procedure. The rate of reintervention for
limb occlusion or stenosis is low, and the timing of reinter-
vention is early (3 months), with most patients needing an
open procedure. Treatment for endoleaks occurs approxi-
mately 1 year after implantation. Migration is a long-term
risk, and like treatment of endoleaks, it is most often
amendable to a minimally invasive procedure.
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